Monaco Asset Management SAM Has $6.06 Million Holdings in Arvinas, Inc. $ARVN

Monaco Asset Management SAM cut its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 21.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 710,936 shares of the company’s stock after selling 190,000 shares during the period. Arvinas makes up 0.4% of Monaco Asset Management SAM’s investment portfolio, making the stock its 16th biggest holding. Monaco Asset Management SAM’s holdings in Arvinas were worth $6,057,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ARVN. Acadian Asset Management LLC lifted its position in shares of Arvinas by 791.1% in the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock worth $10,498,000 after buying an additional 1,267,593 shares during the last quarter. Millennium Management LLC raised its stake in shares of Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after acquiring an additional 885,483 shares in the last quarter. Armistice Capital LLC bought a new stake in shares of Arvinas during the 2nd quarter worth $4,122,000. AQR Capital Management LLC boosted its holdings in Arvinas by 493.2% during the second quarter. AQR Capital Management LLC now owns 614,457 shares of the company’s stock valued at $4,522,000 after acquiring an additional 510,881 shares during the period. Finally, Velan Capital Investment Management LP acquired a new stake in Arvinas in the 2nd quarter valued at approximately $3,680,000. 95.19% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Noah Berkowitz sold 5,685 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $67,594.65. Following the completion of the transaction, the insider owned 163,938 shares in the company, valued at $1,949,222.82. This trade represents a 3.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Randy Teel sold 4,403 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $52,351.67. Following the completion of the sale, the chief executive officer owned 154,482 shares in the company, valued at $1,836,790.98. This trade represents a 2.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 16,238 shares of company stock worth $193,070. Company insiders own 4.73% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ARVN shares. Citigroup raised Arvinas from a “neutral” rating to a “buy” rating and increased their price objective for the company from $10.00 to $15.00 in a research report on Tuesday, January 6th. Stephens raised their price target on shares of Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, November 10th. BTIG Research boosted their price objective on shares of Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Barclays upped their price objective on shares of Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, Wells Fargo & Company decreased their target price on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Ten equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $13.12.

Arvinas Stock Down 3.6%

NASDAQ ARVN opened at $11.99 on Friday. The stock has a market cap of $770.00 million, a P/E ratio of -14.80 and a beta of 1.88. The company’s 50-day simple moving average is $12.36 and its 200 day simple moving average is $10.38. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $19.05.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.